JP Morgan Chase’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

JP Morgan Chase’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-35,000	Closed	-$214K	–	5959
2020 Q2	$214K	Buy	35,000 +2,500	+8%	+$10.3K	﹤0.01%	4226
2020 Q1	$74K	Buy	+32,500	New	+$138K	﹤0.01%	4613
2019 Q2	–	Sell	-40,000	Closed	-$536K	–	6122
2019 Q1	$536K	Buy	+40,000	New	+$456K	﹤0.01%	4173
2018 Q2	–	Sell	-50,000	Closed	-$859K	–	5775
2018 Q1	$859K	Buy	+50,000	New	+$975K	﹤0.01%	3764
2016 Q1	–	Sell	-50,000	Closed	-$2.08M	–	5057
2015 Q4	$2.08M	Buy	+50,000	New	+$1.68M	﹤0.01%	2738

JP Morgan Chase's FPRX Position: Q2 2021 in Review

JP Morgan Chase sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 649,231 shares — an estimated $24.5M sold.

JP Morgan Chase first reported a position in FPRX in Q3 2014 and held it in 23 quarters. The position peaked at $24.5M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

JP Morgan Chase reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
JP Morgan Chase sold 649,231 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $24.5M.
JP Morgan Chase first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 23 quarters.
JP Morgan Chase's Five Prime Therapeutics, Inc. position peaked at $24.5M in Q1 2021.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.